Biotechnology
Experiment showed that Jemincare's neutralizing antibody JMB2002 would likely keep the potency against the South African mutant
SHANGHAI, Feb. 8, 2021 /PRNewswire/ -- On February 7, 2021, scientists from Jemincare Shanghai Research Institute published a preprint paper on BioRxiv, the paper entitled "A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prop...
2021-02-09 11:18
1650
Longevity Acquisition Corporation Announces 4D pharma Clinical Trial Collaboration and Supply Agreement for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onFebruary 8, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Liv...
2021-02-08 21:00
7469
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced multiple clinical advancements for its proprieta...
2021-02-05 21:00
5737
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinic...
2021-02-04 21:00
5137
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®)...
2021-02-03 23:45
5416
Dyadic and TurtleTree Scientific enter strategic partnership
SAN FRANCISCO, Feb. 2, 2021 /PRNewswire/ -- Dyadic International, Inc.
2021-02-02 22:00
1358
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
* Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial * Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy pot...
2021-02-01 14:00
3476
Transnetyx, One Codex Build Strategic Partnership to Provide a Complete Microbiome Analysis Service for Both Mice and Humans
MEMPHIS, Tenn., Jan. 27, 2021 /PRNewswire/ -- Transnetyx, Inc. announced today its collaboration with One Codex on an end-to-end microbiome sequencing and analysis service. This offering will be driven by Transnetyx's wide-reaching global footprint in the model organism community and One Codex's ...
2021-01-28 03:29
1238
Neurophth Therapeutics Further Expands Ocular Gene Therapy Expertise with Appointment of Qiutang Li, Ph.D., as Chief Scientific Officer
WUHAN, China and NEWARK, Del., Jan. 27, 2021 /PRNewswire/ -- Wuhan Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases, today announced the appointment of Qiutang Li, Ph.D., as Chief Scientific Off...
2021-01-27 21:00
1496
Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China
BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial inChina to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of its anti-CTLA4 monoclonal antibody (YH001)...
2021-01-26 23:45
1278
Samsung Biologics Reports 66% Increase in 2020 Revenue Achieving "1 Trillion Won" Target Sales
INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) reported its fourth quarter and full-year 2020 financial results indicating strong business performance, benefitting from increased sales across all plants and significant business agility and operating excelle...
2021-01-26 15:00
6200
BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...
2021-01-26 01:18
5828
China Biologic Announces Extraordinary General Meeting of Shareholders
BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has called an extraordinary general meeting of shareholders (the "EGM...
2021-01-25 21:44
8971
Happiness Biotech Announces Financial Results for the Six Months Ended September 30, 2020 and Provides Guidance For the Whole Fiscal Year Ending March 31, 2021
NANPING, China, Jan. 22, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, today announced its unaudited financial results for the six months endedSeptember 30, 2020 and provided the guida...
2021-01-22 21:00
11286
Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy
WUHAN, China and NEWARK, DE., Jan. 19, 2021 /PRNewswire/ -- Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy company (hereafter Neurophth), and AAVnerGene Inc., a specializing AAV technology company, today announced a strategic partnership to provide ...
2021-01-19 14:05
1471
Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy
SUZHOU, China, Jan. 18, 2021 /PRNewswire/ -- Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure Genetics' proprietary VELPTM platform to develop next-generation gene therapies. This new collaboration combines Boeh...
2021-01-18 22:00
2022
Senhwa Biosciences Presents Positive Cholangiocarcinoma Data
TAIPEI and SAN DIEGO, Jan. 15, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announces that promising clinical data from their global phase...
2021-01-15 22:00
2801
Huami to Host 2021 Strategy and Outlook Investor Fireside Chat with CEO Wang Huang on January 22
BEIJING, Jan. 14, 2021 /PRNewswire/ -- Huami Corp. (NYSE: HMI) today announced that it will hold a Fireside Chat conference call for investors on Friday,22 January 2021. The company will discuss its 2021 strategies for consumer and industrial health technologies, including its product plans annou...
2021-01-14 19:00
10514
Samsung Biologics Shares 'Vision' for Next Decade at the 39th Annual JP Morgan Healthcare Conference
INCHEON, South Korea, Jan. 13, 2021 /PRNewswire/ -- Samsung Biologics (207940.KS) set forth its dynamic growth plan for the next decade at the 2021 Annual JP Morgan Healthcare Conference.John Rim, newly appointed President and CEO, unveiled a multidimensional business plan for the company to furt...
2021-01-13 23:17
7487
GenScript Submits Application with FDA for Use of cPass™ SARS-CoV-2 Neutralization Antibody Test in Convalescent Plasma Screening
PISCATAWAY, N.J., Jan. 13, 2021 /PRNewswire/ -- GenScript USA Inc., the world's leading research reagent provider, announced today that it has submitted an application to the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 N...
2021-01-13 20:30
5369
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8703
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5845
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5183